Heska (NASDAQ: HSKA) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, profitability and risk.
Volatility and Risk
Heska has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 2.19, indicating that its share price is 119% more volatile than the S&P 500.
This table compares Heska and Cidara Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings and price targets for Heska and Cidara Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Heska presently has a consensus price target of $116.50, suggesting a potential upside of 14.76%. Cidara Therapeutics has a consensus price target of $15.50, suggesting a potential upside of 195.24%. Given Cidara Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Cidara Therapeutics is more favorable than Heska.
Valuation & Earnings
This table compares Heska and Cidara Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Heska||$129.34 million||5.86||$9.95 million||$2.07||49.04|
|Cidara Therapeutics||N/A||N/A||-$55.72 million||($3.18)||-1.65|
Heska has higher revenue and earnings than Cidara Therapeutics. Cidara Therapeutics is trading at a lower price-to-earnings ratio than Heska, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
89.2% of Heska shares are held by institutional investors. Comparatively, 64.1% of Cidara Therapeutics shares are held by institutional investors. 15.9% of Heska shares are held by insiders. Comparatively, 15.2% of Cidara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Heska beats Cidara Therapeutics on 10 of the 13 factors compared between the two stocks.
Heska Company Profile
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps. This segment also provides veterinary imaging instruments and services, such as digital radiography solutions and ultrasound systems, as well as sells mobile digital radiography products; Cloudbank, a Web-based image storage solution; ViewCloud, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; TRI-HEART Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. Its Other Vaccines, Pharmaceuticals and Products segment offers bovine vaccines primarily under the Titanium and MasterGuard brands; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. The company sells its products to veterinarians through a field organization, a telephone sales force, and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is headquartered in Loveland, Colorado.
Cidara Therapeutics Company Profile
Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-infectives for the treatment of diseases. Its lead product candidate is rezafungin acetate, a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. It is also developing antibody-drug conjugates for multidrug-resistant bacterial infections that directly kill pathogens and also direct a patient's immune system to attack and eliminate bacterial, fungal, or viral pathogens. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.